Effect of Pravastatin on Levels of Malondealdehyde (MDA) And Endothelin-1 (ET-1) Preeclampsia Model Rats
https://doi.org/10.47836/mjmhs.19.1.13
- Author:
Andriyanti
1
,
2
;
Restiningsih
1
;
Bambang Rahardjo
3
;
Mukhamad Nooryanto
3
;
Sri Winarsih
4
;
Nur Permatasari
5
;
Anin Indriani
3
Author Information
1. Master of Midwifery, Faculty of Medicine, Universitas Brawijaya, Indonesia&
2. Midwifery Study Programme, Faculty of Medicine, Universitas Airlangga, Indonesia
3. Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Brawijaya/ Saiful Anwar General Hospital, Indonesia
4. Department of Microbiology, Faculty of Medicine, Universitas Brawijaya, Indonesia
5. Department of Pharmacology, Faculty of Medicine, Universitas Brawijaya, Indonesia
- Publication Type:Journal Article
- Keywords:
Preeclampsia, Pravastatin, MDA, ET-1, Nitric oxide
- From:Malaysian Journal of Medicine and Health Sciences
2023;19(No.1):89-95
- CountryMalaysia
- Language:English
-
Abstract:
Introduction: Pravastatin is known to have a number of pleiotropic effects including reducing endothelial dysfunction, anti-inflammatory, antioxidants, conangiogenic, and antitrombotic. Pravastatin through the pleitropic effect
is expected to be one of the alternative therapies to prevent preeclampsia. The limited strategy for prevention and
treatment of preeclampsia is due to the unknown etiology and pathogenesis. These two markers are thought to
contribute to the occurrence of preeclampsia although they cause it in two different pathways. MDA is a marker of
oxidative stress as an end product of lipid peroxidation. ET-1 is a vasoconstrictor that plays a role in the pathogenesis
of preeclampsia through increasing anti-angiogenic properties. Aim: to determine the effect of pravastatin on serum
levels of MDA and ET-1 in preeclampsia rat models. Methods: This study consisted of 5 groups; negative control/
K(-) consisted of normal pregnant rats, positive control/ K(+) consisted of rat model of preeclampsia (rat model of preeclampsia induced by administration of L-NAME at a dose of 125 mg/kg BW/day since gestational age 13-19 days),
treatment groups 1, 2, and 3 (rat model of preeclampsia given pravastatin with 3 different doses; 2 mg/day (P1), 4
mg/day (P2) and 8 mg/day(P3)) at 13-19 days of gestation. The rat model of preeclampsia was determined based on
blood pressure > 140/90 with urine protein > +1. After termination, blood was drawn to measure serum MDA and
ET-1 levels. Results: Serum levels of MDA and ET-1 were decreased in groups P2 and P3 compared to groups K(+).
Statistically, there was a significant difference in the mean levels of MDA (p=0.001) and ET-1 (p=0.000) between
each group. Conclusion: Pravastatin can prevent preeclampsia by decreasing MDA and ET-1.
- Full text:11.2023my1413.pdf
